Mark Gentz, DO
Infectious Disease · Midlothian, VANPI 1033153465
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,345 of the $7,442 with a category attached, or 85.3%. It is spread thinly across 29 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,395 and has fallen 55.3% since, to $1,070 in 2025. Among infectious disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Melinta Therapeutics, LLC$1K
- Johnson & Johnson$1K
- AbbVie$932
- Paratek Pharmaceuticals, Inc.$584
- Janssen Products, LP$403
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$4887%
- Food & beverage$6,34585%
- Education$6108%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 44 | $1,302 |
| Melinta Therapeutics, LLC | 33 | $1,244 |
| Johnson & Johnson(2 entities) | 47 | $1,071 |
| AbbVie(2 entities) | 21 | $932 |
| Paratek Pharmaceuticals, Inc. | 23 | $584 |
| Janssen Products, LP | 6 | $403 |
| Merck | 16 | $388 |
| Gilead | 19 | $386 |
| Shionogi Inc | 19 | $239 |
| Organogenesis Inc. | 3 | $172 |
| Exact Sciences | 5 | $103 |
| Theratechnologies Inc. | 6 | $103 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $102 |
| Dexcom, Inc. | 3 | $63 |
| Novo Nordisk | 4 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Lifenet Health | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Amgen | 2 | $30 |
| Next Science LLC | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Napo Pharmaceuticals Inc | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
| Insmed, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,442 in reported general payments places this provider in the 90th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 76 | $331,021 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 35 | $142,519 |
| Daptomycin | 114 | $107,699 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 19 | $97,598 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $47,716 |
| TivicayDolutegravir Sodium | 11 | $41,790 |
| ErtapenemErtapenem Sodium | 42 | $14,534 |
| Cefepime Hcl | 34 | $11,868 |
| CeftriaxoneCeftriaxone Sodium | 92 | $9,602 |
| Ampicillin Sodium | 19 | $6,841 |
| Meropenem | 24 | $4,109 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 18 | $3,850 |
| Cefazolin Sodium | 43 | $2,107 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 11 | $1,847 |
| Vancomycin Hcl | 14 | $1,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $386 | $473,540111 claims |
| Janssen Products, LPSymtuza | $403 | $97,59819 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay | $1,302 | $89,50622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 194 infectious disease providers in Virginia.
Other infectious disease in Midlothian
- Andrea GonzalezMidlothian$17K
- Sarika TripathiMidlothian$1K
- Christopher BettacchiMarion$243K
- Stephen WeinrothFairfax$157K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
- Valerie RiddleBumpass$83K
- Edward OldfieldNorfolk$81K
- William FurlongArlington$68K
- Frederick HaydenCharlottesville$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.